AR121441A1 - Anticuerpos anti-axl y composiciones - Google Patents
Anticuerpos anti-axl y composicionesInfo
- Publication number
- AR121441A1 AR121441A1 ARP210100499A ARP210100499A AR121441A1 AR 121441 A1 AR121441 A1 AR 121441A1 AR P210100499 A ARP210100499 A AR P210100499A AR P210100499 A ARP210100499 A AR P210100499A AR 121441 A1 AR121441 A1 AR 121441A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- nos
- amino acid
- acid sequences
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicación 1: Un anticuerpo anti-AXL o una porción de unión a antígeno de este, caracterizado porque el anticuerpo se une al mismo epítopo de AXL humano que un anticuerpo que comprende: a) una HC que comprende las secuencias de aminoácidos de las SEQ ID Nº 43 y 61 y una LC que comprende las secuencias de aminoácidos de las SEQ ID Nº 44 y 62; o b) una HC que comprende las secuencias de aminoácidos de las SEQ ID Nº 13 y 61 y una LC que comprende las secuencias de aminoácidos de las SEQ ID Nº 14 y 62; c) una cadena pesada (HC) que comprende las secuencias de aminoácidos de las SEQ ID Nº 3 y 61 y una cadena ligera (LC) que comprende las secuencias de aminoácidos de las SEQ ID Nº 4 y 62; d) una HC que comprende las secuencias de aminoácidos de las SEQ ID Nº 23 y 61 y una LC que comprende las secuencias de aminoácidos de las SEQ ID Nº 24 y 62; e) una HC que comprende las secuencias de aminoácidos de las SEQ ID Nº 33 y 61 y una LC que comprende las secuencias de aminoácidos de las SEQ ID Nº 34 y 62; f) una HC que comprende las secuencias de aminoácidos de las SEQ ID Nº 53 y 61 y una LC que comprende las secuencias de aminoácidos de las SEQ ID Nº 54 y 62. Reivindicación 27: Un método para tratar el cáncer en un paciente, caracterizado porque administrar a dicho paciente una cantidad terapéuticamente eficaz del anticuerpo anti-AXL o la porción de unión al antígeno de acuerdo con cualquiera de las reivindicaciones 1 - 18, la composición farmacéutica de acuerdo con la reivindicación 19 ó 20, o la molécula de unión biespecífica de acuerdo con la reivindicación 26.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982852P | 2020-02-28 | 2020-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121441A1 true AR121441A1 (es) | 2022-06-08 |
Family
ID=75426640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100499A AR121441A1 (es) | 2020-02-28 | 2021-02-26 | Anticuerpos anti-axl y composiciones |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11807688B2 (es) |
| EP (1) | EP4110824A1 (es) |
| JP (1) | JP7748377B2 (es) |
| KR (1) | KR20220148237A (es) |
| CN (1) | CN115210263A (es) |
| AR (1) | AR121441A1 (es) |
| AU (1) | AU2021225490B2 (es) |
| BR (1) | BR112022015977A2 (es) |
| CA (1) | CA3170975A1 (es) |
| CL (1) | CL2022002259A1 (es) |
| CO (1) | CO2022012159A2 (es) |
| IL (1) | IL295596A (es) |
| MX (1) | MX2022010670A (es) |
| MY (1) | MY209381A (es) |
| PE (1) | PE20221783A1 (es) |
| PH (1) | PH12022552041A1 (es) |
| TW (1) | TW202146455A (es) |
| WO (1) | WO2021171257A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026001894A1 (zh) * | 2024-06-24 | 2026-01-02 | 上海医药集团生物治疗技术有限公司 | 靶向axl的嵌合抗原受体及其用途 |
| CN119912586B (zh) * | 2024-12-31 | 2025-09-30 | 四川省肿瘤医院 | 基于受体酪氨酸激酶家族axl改造的嵌合抗原受体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| KR101568051B1 (ko) | 2007-11-15 | 2015-11-10 | 추가이 세이야쿠 가부시키가이샤 | Ａｎｅｘｅｌｅｋｔｏ에 결합하는 단일클론항체, 및 그의 이용 |
| BR112012027995A2 (pt) | 2010-06-18 | 2017-01-10 | Genentech Inc | anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl |
| CA2969879A1 (en) | 2014-12-18 | 2016-06-23 | Bergen Teknologioverforing As | Anti-axl antagonistic antibodies |
| EP3319993B1 (en) * | 2015-07-10 | 2020-01-15 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| PH12018502112B1 (en) * | 2016-04-12 | 2024-03-27 | Servier Lab | Anti-tim-3 antibodies and compositions |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| WO2019197506A1 (en) * | 2018-04-10 | 2019-10-17 | Genmab A/S | Axl-specific antibodies for cancer treatment |
-
2021
- 2021-02-26 CA CA3170975A patent/CA3170975A1/en active Pending
- 2021-02-26 WO PCT/IB2021/051636 patent/WO2021171257A1/en not_active Ceased
- 2021-02-26 MX MX2022010670A patent/MX2022010670A/es unknown
- 2021-02-26 IL IL295596A patent/IL295596A/en unknown
- 2021-02-26 PH PH1/2022/552041A patent/PH12022552041A1/en unknown
- 2021-02-26 PE PE2022001857A patent/PE20221783A1/es unknown
- 2021-02-26 KR KR1020227033462A patent/KR20220148237A/ko active Pending
- 2021-02-26 AU AU2021225490A patent/AU2021225490B2/en active Active
- 2021-02-26 AR ARP210100499A patent/AR121441A1/es unknown
- 2021-02-26 MY MYPI2022004441A patent/MY209381A/en unknown
- 2021-02-26 EP EP21717200.6A patent/EP4110824A1/en active Pending
- 2021-02-26 US US17/186,465 patent/US11807688B2/en active Active
- 2021-02-26 BR BR112022015977A patent/BR112022015977A2/pt unknown
- 2021-02-26 JP JP2022551247A patent/JP7748377B2/ja active Active
- 2021-02-26 CN CN202180017213.3A patent/CN115210263A/zh active Pending
- 2021-03-02 TW TW110107402A patent/TW202146455A/zh unknown
-
2022
- 2022-08-18 CL CL2022002259A patent/CL2022002259A1/es unknown
- 2022-08-25 CO CONC2022/0012159A patent/CO2022012159A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20221783A1 (es) | 2022-11-16 |
| CA3170975A1 (en) | 2021-09-02 |
| JP7748377B2 (ja) | 2025-10-02 |
| CO2022012159A2 (es) | 2022-10-31 |
| WO2021171257A1 (en) | 2021-09-02 |
| AU2021225490A1 (en) | 2022-09-15 |
| JP2023515821A (ja) | 2023-04-14 |
| MY209381A (en) | 2025-07-04 |
| EP4110824A1 (en) | 2023-01-04 |
| PH12022552041A1 (en) | 2023-11-29 |
| TW202146455A (zh) | 2021-12-16 |
| CL2022002259A1 (es) | 2023-04-14 |
| MX2022010670A (es) | 2022-09-23 |
| AU2021225490B2 (en) | 2025-11-27 |
| US20210269532A1 (en) | 2021-09-02 |
| CN115210263A (zh) | 2022-10-18 |
| US11807688B2 (en) | 2023-11-07 |
| BR112022015977A2 (pt) | 2022-10-11 |
| KR20220148237A (ko) | 2022-11-04 |
| IL295596A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231851A1 (es) | Proteinas que se unen a nkg2d, cd16 y clec12a | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| AR111203A1 (es) | Inmunoconjugados | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| AR111209A2 (es) | Composición de anticuerpo her2 | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| AR110101A1 (es) | Miembros de unión (2) | |
| AR072897A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| AR123480A1 (es) | Moléculas de unión terapéuticas | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| AR109533A2 (es) | Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| AR085955A1 (es) | Proteinas de union al antigeno | |
| PE20221263A1 (es) | Agentes de union a ilt3 y metodos de uso de los mismos | |
| MX2024009976A (es) | Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso. | |
| PE20230414A1 (es) | Agentes de fijacion a tie2 y metodos de uso | |
| AR121441A1 (es) | Anticuerpos anti-axl y composiciones | |
| ZA202305217B (en) | Anti-tigit antibody, and pharmaceutical composition and use thereof | |
| AR095499A1 (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| CO2025002301A2 (es) | Anticuerpos anti-ccr8 y métodos de uso | |
| MX2024010334A (es) | Composicion farmaceutica que comprende anticuerpo biespecifico anti-ctla4-anti-pd-1 y chiauranib. |